Novexel Appoints Chief Financial Officer
News Jan 23, 2006
Novexel has announced the appointment of Gordon Waldron as Chief Financial Officer with immediate effect.
Gordon joins Novexel from the French biotechnology company Synt:em S.A., where he held the position of Vice President Finance & CFO from 1997.
During this time he built a pan-European, blue chip investor base, raised €30 million in private equity financing, negotiated a technology out licensing deal with a US public biotech company and ultimately the sale of Synt:em to a private French pharmaceutical company.
Prior to Synt:em, Gordon was Group Finance Manager for Europe, Africa and Middle East at Texas Instruments Software in the UK, which involved Group Financial and Management Accounting for 17 legal entities and a distributor network across 14 countries.
During this time, Gordon participated in negotiations for various MBO/entity disposal projects.
Gordon also worked for the Paris branch of Texas Instruments Software where he was Finance Director of their start-up subsidiary.
Previously, Gordon held Controller positions at Spie Batignolles in both the US and France.
Iain Buchanan, CEO of Novexel, commented, "I am delighted to welcome Gordon to Novexel in this key role. His breadth of financial experience will be of tremendous value as we continue to build the Company in 2006 and beyond."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019